54 recruiting. 54 Phase 2, 12 Phase 3, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 54 | Recruiting 54 |
| Phase 3 | 12 | Recruiting 12 |
| Phase 1 | 5 | Recruiting 5 |
Follow Ischemic Stroke: new trials by email Literature Review of Ischemic Stroke trials Research Report on Ischemic Stroke
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Reduction of SystemiC Inflammation After Ischemic Stroke by Intravenous DNase Administration (ReSCInD) Dornase Alfa, Isotonic Saline Solution - Ischemic Stroke, Inflammatory Response | Phase 2 | Recruiting | Ludwig-Maximilians - University of Munich | 36 | 2026-10-01 | 2026-09-11 |
| A Study to Evaluate the Intracranial Arterial Recanalization With Multiple Doses of LT3001 Drug Product in AIS Participant LT3001 Drug Product - Acute Ischemic Stroke | Phase 2 | Recruiting | Lumosa Therapeutics Co., Ltd. | 10 | 2026-10-01 | 2026-10-22 |
| Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL-2) Anisodine Hydrobromide, Anisodine Hydrobromide Placebo - Acute Ischemic Stroke | Phase 2 | Recruiting | Capital Medical University | 204 | 2026-09-06 | 2026-10-13 |
| Safety and Efficacy of J147 in Acute Ischemic Stroke J147 Emulsion for Injection, Placebo - Acute Ischemic Stroke | Phase 2 | Recruiting | Abrexa Pharmaceuticals, Inc. | 196 | 2026-07-22 | 2026-08-24 |
| Human Placenta-derived 3D Mesenchymal Stem Cells(Guojianqingke) Human Placenta-derived 3D Mesenchymal Stem Cells (Guojiangqingke) - Acute Ischemic Stroke | Phase 1 / Phase 2 | Recruiting | Chinese PLA General Hospital | 24 | 2026-06-01 | 2026-06-09 |
| Minocycline After Successful Endovascular Thrombectomy Recanalization in Acute Anterior Circulation Large Vessel Occlusion (ATTRACTION-MINOA) Minocycline hydrochloride capsule, Placebo capsules of Minocycline hydrochloride capsules - Acute Ischemic Stroke, Vessel Occlusion | Phase 2 / Phase 3 | Recruiting | Xiang Luo | 860 | 2026-05-21 | 2026-05-27 |
| Minocycline After Successful Endovascular Thrombectomy Recanalization in Posterior Circulation Arterial Occlusion (ATTRACTION-MINOP) Minocycline hydrochloride capsule, Placebo capsules of Minocycline hydrochloride capsules - Acute Ischemic Stroke, Endovascular Thrombectomy | Phase 2 / Phase 3 | Recruiting | Xiang Luo | 234 | 2026-05-19 | 2026-05-22 |
| A Study of TAK-755 in Adults With Acute Ischemic Stroke TAK-755, Placebo - Acute Ischemic Stroke | Phase 2 | Recruiting | Takeda | 222 | 2026-05-17 | 2026-08-14 |
| Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours of Onset With Prourokinase prourokinase - Acute Ischemic Stroke | Phase 2 | Recruiting | General Hospital of Shenyang Military Region | 122 | 2026-05-06 | 2026-06-30 |
| Advancing Reperfusion Therapy for Ischemic Stroke: Safety and Efficacy of Anakinra for Futile Reperfusion Following Endovascular Treatment in Patients With Acute Ischemic Stroke High-dose Anakinra, Low-dose Anakinra, Standard medical treatment - Stroke Acute, Endovascular Treatment | Phase 2 | Recruiting | Beijing Tiantan Hospital | 159 | 2026-04-08 | 2026-10-16 |
| Intra-arterial Methylprednisolone After Endovascular Thrombectomy The methylprednisolone sodium succinate group, The placebo group - Ischemia Stroke, Thrombectomy | Phase 2 | Recruiting | Tang-Du Hospital | 210 | 2026-03-31 | 2026-04-08 |
| Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) Tenecteplase - Ischemic Stroke | Phase 2 | Recruiting | General Hospital of Shenyang Military Region | 120 | 2026-03-25 | 2026-04-01 |
| Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours of Onset With Tenecteplase (RITIS-TNK2) Tenecteplase - Ischemic Stroke | Phase 2 | Recruiting | General Hospital of Shenyang Military Region | 198 | 2026-03-25 | 2026-04-01 |
| Intra-Arterial Tenecteplase to Improve the Microvascular Hemodynamics After Mechanical Thrombectomy intra-arterial tenecteplase administration - Acute Ischemic Stroke From Large Vessel Occlusion | Phase 2 | Recruiting | University of Pennsylvania | 20 | 2026-02-13 | 2026-08-18 |
| Modulation of Cerebral Ischemia by Albumin Albumin infusion, Placebo Injection - Ischemic Stroke | Phase 2 | Recruiting | University Hospital Hradec Kralove | 100 | 2026-02-03 | 2026-05-06 |
| Minocycline in Stroke Study at Maimonides Minocycline 200mg - Stroke, Ischemia Stroke | Phase 2 / Phase 3 | Recruiting | Joyce Chen | 1164 | 2026-02-02 | 2026-03-19 |
| Tenecteplase Plus Urinary Kallidinogenase for Acute Ischemic Stroke (TUKIS) Human Urinary Kallidinogenase - Ischemic Stroke | Phase 2 | Recruiting | General Hospital of Shenyang Military Region | 200 | 2026-01-20 | 2026-01-23 |
| Study to Assess the Efficacy and Safety of QHRD106 Injection in Acute Ischemic Stroke. QHRD106 Injection (Low-dose group), QHRD106 Injection (Middle-dose group), QHRD106 Injection (High-dose group) - Acute Ischemic Stroke | Phase 2 | Recruiting | Changzhou Qianhong Bio-pharma Co., Ltd. | 320 | 2026-01-19 | 2026-02-09 |
| Thrombolysis in Early Acute Ischemic Stroke Trial-Blood Pressure Management Adjusted BP management group, Usual BP management group - Stroke, Acute Ischemic Stroke | Phase 2 | Recruiting | Shanghai East Hospital | 340 | 2026-01-15 | 2026-01-21 |
| A Study of B2065 in Patients With Acute Ischemic Stroke B2065, Placebo - Acute Ischemic Stroke | Phase 1 / Phase 2 | Recruiting | Tasly Pharmaceutical Group Co., Ltd | 54 | 2025-12-31 | 2026-08-13 |
Showing 20 of 54. Sign in to see all of them.
Stroke (12) · Brain Diseases (3) · cyclopia sequence (3) · Central Nervous System Diseases (2) · Cerebrovascular Disorders (2) · Hemorrhagic Stroke (2) · Acute Disease (1) · Arterial Occlusive Diseases (1) · Brain Infarction (1) · Bronchiolitis Obliterans Syndrome (1) · Cardiovascular Diseases (1) · Cerebral Hemorrhage (1) · Cerebral Infarction (1) · Hypercholesterolemia (1)
Cardiovascular Diseases (53) · Nervous System Diseases (53) · Vascular Diseases (53) · Central Nervous System Diseases (52) · Cerebrovascular Disorders (52) · Brain Diseases (51) · Stroke (42) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Brain Ischemia (3) · Hemorrhage (2) · Infarction (2) · Ischemia (2) · Necrosis (2) · Arterial Occlusive Diseases (1)
Tenecteplase (4) · Minocycline (3) · Injections (2) · Standard of Care (2) · Albumins (1) · Amantadine (1) · Aspirin (1) · Atorvastatin (1) · Clopidogrel (1) · DM199 (1) · Ezetimibe (1) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (1) · Interleukin 1 Receptor Antagonist Protein (1) · Mannitol (1) · Maraviroc (1)
General Hospital of Shenyang Military Region (4) · Xiang Luo (3) · Beijing Tiantan Hospital (2) · University of Melbourne (2) · University of Pennsylvania (2) · Aarhus University Hospital (1) · Abrexa Pharmaceuticals, Inc. (1) · Basking Biosciences, Inc. (1) · Capital Medical University (1) · Chang Gung Memorial Hospital (1) · Changzhou Qianhong Bio-pharma Co., Ltd. (1) · Chinese PLA General Hospital (1) · Corxel Pharmaceuticals (1) · Cytopeutics Sdn. Bhd. (1) · DiaMedica Therapeutics Inc (1)
China (26) · United States (12) · Australia (5) · France (5) · Canada (4) · Belgium (3) · Germany (3) · Japan (3) · United Kingdom (3) · Brazil (2) · Greece (2) · Hungary (2) · Italy (2) · Malaysia (2) · Spain (2)
Xiang Luo (3) · Arthur Liesz, Prof. Dr. (1) · Bijoy Menon, MBBS, MD (1) · Bruce Campbell (1) · Candice Delcourt, Dr (1) · Christopher Favilla, MD (1) · Chuanzhi Duan, MD (1) · Claus Z Simonsen, Professor (1) · Emmanuel Carrera, MD (1) · Eva Mistry, MBBS (1) · Fana Alemseged (1) · Jay Volpi, M.D. (1) · Marguerite Prior, Ph.D. (1) · Michael D Hill, MD (1)
PMID 35188949, PMID 39772606, PMID 39869712, PMID 40705350, PMID 41815317, PMID 42051694, PMID 42082248, PMID 42629154
1UG3NS134619-01A1 (1), 2023 (1), UH3NS125023 (1)